BRAF and melanoma: Immunotherapies such as anti-programmed cell death ligand 1(anti-PD-1) immune checkpoint inhibitor (ICI) and anti-cytotoxic T lymphocyte antigen-2 (anti-CTLA-4) ICI, as well as targeted antitumor treatments, including B-Raf proto-oncogene (BRAF) and mitogen-activated protein-kinase-kinase (MEK) inhibitors, have revolutionized melanoma treatment [1, 2].